Still unlicensed in humans outside of research investor.lilly.com/news-releases/ TRIUMPH-1: #retatrutide topline data Phase 3, n=2,339, 80 wk, obesity without diabetes (efficacy estimand): 12 mg: -28.3% body weight (-31.9 kg) 9 mg: -25.9% | 4 mg: -19.0% | Placebo: -2.2% 30% weight loss: 45.3% vs 0.5% 104-wk extension (BMI 35, n=532), 12 mg MTD: -30.3% Cross-trial context (obesity, no diabetes): STEP-1 SEMA 2.4 mg, 68 wk: -14.9% SURMOUNT-1 TZP 15 mg, 72 wk: -20.9% TRIUMPH-1 RETA 12 mg, 80 wk: -28.3% But: Topline press release
By slowing cholesterol production, they lower LDL cholesterol levels in the bloodstream
95% CI, 0.63 to 0.88
In an oral cancer cell line, quercetin induced apoptosis and reversed drug resistance to vincristine (Oncovin) (Yuan 2015)
In December 2025, the FDA approved the oral semaglutide option via Wegovy pills, specifically for those who prefer tablets over injections
Other Ingredients: (Insoluble) Polyvinylpyrrolidone (INS 1202), (Diluent [INS 460(i)]), Diluent (Starch), Disintegrant (Sodium Starch Glycolate), Disintegrant (INS 468), Talc [INS 553(iii)], Antisticking agent (Stearic acid), Acidity Regulator (INS 330), Amorphous Silicon Dioxide (INS 551), Hydroxy Propyl Methyl Cellulose (INS 464), Ethyl Cellulose (INS 462), Triacetin (INS 1518) and Colours (INS 104 and INS 171)
